Skip to main content
Top
Published in: BMC Medicine 1/2022

01-12-2022 | Public Health | Research article

Opening up safely: public health system requirements for ongoing COVID-19 management based on evaluation of Australia’s surveillance system performance

Authors: Kamalini Lokuge, Katina D’Onise, Emily Banks, Tatum Street, Sydney Jantos, Mohana Baptista, Kathryn Glass

Published in: BMC Medicine | Issue 1/2022

Login to get access

Abstract

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) community transmission was eliminated in Australia from 1/11/2020 to 30/6/2021, allowing evaluation of surveillance system performance in detecting novel outbreaks, including against variants of concern (VoCs). This paper aims to define system requirements for coronavirus disease 2019 (COVID-19) surveillance under future transmission and response scenarios, based on surveillance system performance to date.

Methods

This study described and evaluated surveillance systems and epidemiological characteristics of novel outbreaks based on publicly available data, and assessed surveillance system sensitivity and timeliness in outbreak detection. These findings were integrated with analysis of other critical COVID-19 public health measures to establish future COVID-19 management requirements.

Results

Twenty-five epidemiologically distinct outbreaks and five distinct clusters were identified in the study period, all linked through genomic sequencing to novel introductions from international travellers. Seventy percent (21/30) were detected through community testing of people with acute respiratory illness, and 30% (9/30) through quarantine screening. On average, 2.07% of the State population was tested in the week preceding detection for those identified through community surveillance. From 17/30 with publicly available data, the average time from seeding to detection was 4.9 days. One outbreak was preceded by unexpected positive wastewater results. Twenty of the 24 outbreaks in 2021 had publicly available sequencing data, all of which identified VoCs. A surveillance strategy for future VoCs similar to that used for detecting SARS-CoV-2 would require a 100–1000-fold increase in genomic sequencing capacity compared to the study period. Other essential requirements are maintaining outbreak response capacity and developing capacity to rapidly engineer, manufacture, and distribute variant vaccines at scale.

Conclusions

Australia’s surveillance systems performed well in detecting novel introduction of SARS-CoV-2 while community transmission was eliminated; introductions were infrequent and case numbers were low. Detection relied on quarantine screening and community surveillance in symptomatic members of the general population, supported by comprehensive genomic sequencing. Once vaccine coverage is maximised, future COVID-19 control should shift to detection of SARS-CoV-2 VoCs, requiring maintenance of surveillance systems and testing all international arrivals, alongside greatly increased genomic sequencing capacity. Effective government support of localised public health response mechanisms and engagement of all sectors of the community is crucial to current and future COVID-19 management.
Appendix
Available only for authorised users
Literature
3.
go back to reference Communicable Diseases Network Australia. Australian National Disease Surveillance Plan for COVID-19, Version 2.0, April 2021. 2021. Communicable Diseases Network Australia. Australian National Disease Surveillance Plan for COVID-19, Version 2.0, April 2021. 2021.
4.
go back to reference Australian Government Department of Health, Communicable Diseases Network Australia. Coronavirus disease 2019 (COVID-19) - CDNA National Guidelines for Public Health Units, Version 4.7. 2021. Australian Government Department of Health, Communicable Diseases Network Australia. Coronavirus disease 2019 (COVID-19) - CDNA National Guidelines for Public Health Units, Version 4.7. 2021.
6.
go back to reference Grout L, Katar A, Ouakrim DA, Summers JA, Kvalsvig A, Baker MG, Blakely T, et al. Estimating the failure risk of quarantine systems for preventing COVID-19 outbreaks in Australia and New Zealand. 2021.CrossRef Grout L, Katar A, Ouakrim DA, Summers JA, Kvalsvig A, Baker MG, Blakely T, et al. Estimating the failure risk of quarantine systems for preventing COVID-19 outbreaks in Australia and New Zealand. 2021.CrossRef
8.
go back to reference Abdool Karim SS, de Oliveira T. New SARS-CoV-2 variants — clinical, public health, and vaccine implications. N Engl J Med. 2021;384(19):1866–8.CrossRef Abdool Karim SS, de Oliveira T. New SARS-CoV-2 variants — clinical, public health, and vaccine implications. N Engl J Med. 2021;384(19):1866–8.CrossRef
10.
go back to reference Public Health England. Public Health England vaccine effectiveness report. 2021. Public Health England. Public Health England vaccine effectiveness report. 2021.
13.
go back to reference Burki T. Global COVID-19 vaccine inequity. Lancet Infect Dis. 2021;21(7):922–3.CrossRef Burki T. Global COVID-19 vaccine inequity. Lancet Infect Dis. 2021;21(7):922–3.CrossRef
16.
go back to reference Dowdle WR. The principles of disease elimination and eradication. MMWR. 1999;48:23–7. Dowdle WR. The principles of disease elimination and eradication. MMWR. 1999;48:23–7.
17.
go back to reference World Health Organization. COVID-19 weekly epidemiological update. 2021. World Health Organization. COVID-19 weekly epidemiological update. 2021.
18.
go back to reference Pinnock H, Barwick M, Carpenter CR, Eldridge S, Grandes G, Griffiths CJ, et al. Standards for Reporting Implementation Studies (StaRI) Statement. Bmj. 2017;356:i6795.CrossRef Pinnock H, Barwick M, Carpenter CR, Eldridge S, Grandes G, Griffiths CJ, et al. Standards for Reporting Implementation Studies (StaRI) Statement. Bmj. 2017;356:i6795.CrossRef
22.
go back to reference World Health Organization. Report of the WHO-China Joint Mission on coronavirus disease 2019 (COVID-19). 2020. World Health Organization. Report of the WHO-China Joint Mission on coronavirus disease 2019 (COVID-19). 2020.
23.
go back to reference Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. PLoS One. 2020;15(6):e0234765.CrossRef Grant MC, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke EL, et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries. PLoS One. 2020;15(6):e0234765.CrossRef
24.
go back to reference Zwartz H. A lot more of us can now get tested for coronavirus. Here’s what you need to know: ABC News; 2020. Zwartz H. A lot more of us can now get tested for coronavirus. Here’s what you need to know: ABC News; 2020.
28.
go back to reference ABC News. Rules on COVID vaccines, testing for quarantine workers tightened after National Cabinet meeting. ABC News. 2021. ABC News. Rules on COVID vaccines, testing for quarantine workers tightened after National Cabinet meeting. ABC News. 2021.
31.
go back to reference Torjesen I. Covid-19: Delta variant is now UK’s most dominant strain and spreading through schools. BMJ. 2021;373:n1445.CrossRef Torjesen I. Covid-19: Delta variant is now UK’s most dominant strain and spreading through schools. BMJ. 2021;373:n1445.CrossRef
32.
go back to reference Havers F, Whitaker M, Self J, et al. Hospitalization of adolescents aged 12–17 years with laboratory-confirmed COVID-19 — COVID-NET, 14 States, March 1, 2020–April 24, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(23):851–7.CrossRef Havers F, Whitaker M, Self J, et al. Hospitalization of adolescents aged 12–17 years with laboratory-confirmed COVID-19 — COVID-NET, 14 States, March 1, 2020–April 24, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(23):851–7.CrossRef
34.
go back to reference Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19. JAMA. 2021;325(7):632.CrossRef Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19. JAMA. 2021;325(7):632.CrossRef
35.
go back to reference Lokuge K, Banks E, Davis S, Roberts L, Street T, O’Donovan D, et al. Exit strategies: optimising feasible surveillance for detection, elimination, and ongoing prevention of COVID-19 community transmission. BMC Med. 2021;19(1):50.CrossRef Lokuge K, Banks E, Davis S, Roberts L, Street T, O’Donovan D, et al. Exit strategies: optimising feasible surveillance for detection, elimination, and ongoing prevention of COVID-19 community transmission. BMC Med. 2021;19(1):50.CrossRef
36.
go back to reference MacIntyre R. Vaccination for COVID-19 control and considerations for Australia. Microbiol Aust. 2021;42(1):30–4.CrossRef MacIntyre R. Vaccination for COVID-19 control and considerations for Australia. Microbiol Aust. 2021;42(1):30–4.CrossRef
37.
go back to reference Crozier A, Rajan S, Buchan I, McKee M. Put to the test: use of rapid testing technologies for covid-19. BMJ. 2021;372:n208.CrossRef Crozier A, Rajan S, Buchan I, McKee M. Put to the test: use of rapid testing technologies for covid-19. BMJ. 2021;372:n208.CrossRef
40.
go back to reference Scott L, Hsiao N-y, Moyo S, Singh L, Tegally H, Dor G, et al. Track Omicron’s spread with molecular data. Science. 2021;374(6574):1454–5.CrossRef Scott L, Hsiao N-y, Moyo S, Singh L, Tegally H, Dor G, et al. Track Omicron’s spread with molecular data. Science. 2021;374(6574):1454–5.CrossRef
42.
go back to reference Bar-Or I, Weil M, Indenbaum V, Bucris E, Bar-Ilan D, Elul M, et al. Detection of SARS-CoV-2 variants by genomic analysis of wastewater samples in Israel. Sci Total Environ. 2021;789:148002.CrossRef Bar-Or I, Weil M, Indenbaum V, Bucris E, Bar-Ilan D, Elul M, et al. Detection of SARS-CoV-2 variants by genomic analysis of wastewater samples in Israel. Sci Total Environ. 2021;789:148002.CrossRef
47.
go back to reference Thulin L. Why the U.S. Is struggling to track coronavirus variants: Smithsonian Magazine; 2021. Thulin L. Why the U.S. Is struggling to track coronavirus variants: Smithsonian Magazine; 2021.
52.
go back to reference COVID-19 Genomics UK Consortium. Summary report: COGUK geographic coverage of SARSCoV2 sample sequencing. 2021. COVID-19 Genomics UK Consortium. Summary report: COG­UK geographic coverage of SARS­CoV­2 sample sequencing. 2021.
56.
go back to reference Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC, et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet (London, England). 2021;398(10308):1377–80.CrossRef Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC, et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet (London, England). 2021;398(10308):1377–80.CrossRef
59.
go back to reference Anderson EL. Recommended solutions to the barriers to immunization in children and adults. Mo Med. 2014;111(4):344–8.PubMedPubMedCentral Anderson EL. Recommended solutions to the barriers to immunization in children and adults. Mo Med. 2014;111(4):344–8.PubMedPubMedCentral
61.
go back to reference Murphy J, Vallières F, Bentall RP, Shevlin M, McBride O, Hartman TK, et al. Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nat Commun. 2021;12(1):29.CrossRef Murphy J, Vallières F, Bentall RP, Shevlin M, McBride O, Hartman TK, et al. Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nat Commun. 2021;12(1):29.CrossRef
Metadata
Title
Opening up safely: public health system requirements for ongoing COVID-19 management based on evaluation of Australia’s surveillance system performance
Authors
Kamalini Lokuge
Katina D’Onise
Emily Banks
Tatum Street
Sydney Jantos
Mohana Baptista
Kathryn Glass
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2022
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-022-02344-x

Other articles of this Issue 1/2022

BMC Medicine 1/2022 Go to the issue